Recursion Pharmaceuticals Inc

Stock Chart, Company Information, and Scan Results

$5.72(as of Jul 10, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Recursion Pharmaceuticals Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$5.72
Ticker SymbolRXRX
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees800
CountyUSA
Market Cap$2,316.7M
EBIDTA-442.5M
10-Day Moving Average5.27
P/E Ratio-4.14
20-Day Moving Average5.17
Forward P/E Ratio0.00
50-Day Moving Average4.87
Earnings per Share-1.69
200-Day Moving Average6.29
Profit Margin-3,965.99%
RSI61.00
Shares Outstanding399.60M
ATR0.42
52-Week High12.36
Volume28,501,325
52-Week Low3.79
Most Recent Support Level4.80
Book Value1,034.8M
Most Recent Resistance Level5.44
P/B Ratio1.86
Upper Keltner6.10
P/S Ratio32.66
Lower Keltner4.23
Debt-to-Equity Ratio6.10
Next Earnings Date08/12/2025
Cash Surplus406.9M
Next Ex-Dividend DateUnknown

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.